Systemic chemotherapy for advanced hepatocellular carcinoma has been “unsolved”: three previous large-scale international studies all ended with negative results, but the EACH study led by Chinese scholar Prof. Qin Shukui has finally revealed the only positive result in the study of systemic chemotherapy for hepatocellular carcinoma. The study selected the FOLFOX regimen, which is classically used for colorectal cancer treatment, and showed significant differences in overall survival, progression-free survival, remission rate, and disease control rate compared to the control group, demonstrating for the first time that systemic chemotherapy can bring survival benefits to patients with advanced liver cancer. Previous studies have demonstrated that the FOLFOX regimen of oxaliplatin + calcium folinate + fluorouracil can reduce the risk of death by 20% in patients with early-stage colorectal cancer and has become the standard of care for colorectal and gastric cancers, but it is the first time that systemic chemotherapy has been used for liver cancer with positive results. Also for advanced colorectal cancer, the CLOCC study by European scholars applying radiofrequency ablation in combination with chemotherapy showed the advantages of integrating chemotherapy + radiofrequency ablation for liver metastases: its progression-free survival was significantly longer than that of chemotherapy alone, providing a new treatment option for advanced colorectal cancer patients with liver metastases only, further demonstrating the value of local treatment for advanced tumors. Another CELIM study of liver metastases from advanced colorectal cancer demonstrated that colorectal cancer patients with liver metastases, even with cetuximab combined with FOLFOX or FOLFIRI chemotherapy regimens, still achieved an objective remission rate of 62% and a microscopic residual-free resection rate of 34% for liver metastases. This strategy can increase the resection rate more than 1-fold compared to chemotherapy alone, thus making long-term survival possible for patients with advanced disease.